The intervention showed a positive impact on knowledge and confidence gains, in addition to anticipated performance in clinical practice that should enhance the health outcomes of patients affected by HER2+ G&CRC at the metastatic stage. The gene discussed is ERBB2; the disease is colorectal carcinoma.